The following video is part of our "Motley Fool Conversations" series, in which, David Williamson, health-care editor and analyst, and Austin Smith, consumer-goods editor and analyst, discuss topics around the investing world.
In today's edition, David and Austin take a look at the worst health-care performers of 2012, focusing on the worst performer of the year, Dendreon. This video reflects back on the year that was but also takes a look at what Dendreon needs to do to be successful in 2012 and the threats on the company's horizon.
Looking for our prediction for 2012? Check out The Motley Fool's brand new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
At the time thisarticle was published Austin Smith owns no shares of the companies listed above. David Williamson owns shares of Dendreon and Johnson & Johnson. The Motley Fool owns shares of Devon Energy and Dendreon.Motley Fool newsletter serviceshave recommended buying shares of Vertex Pharmaceuticals. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.